Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Binding together for biotherapeutics
February 2018
SHARING OPTIONS:

DARLINGTON, U.K.—The Centre for Process Innovation (CPI) entered 2018 with news of a collaboration between itself, GlycoSeLect UK Ltd., ForteBio Pall Life Science and Allergan Biologics Ltd. This initiative will focus on filling the need for new glycoanalytical approaches to address demands in the biotherapeutics market. Roughly two-thirds of biotherapeutics are glycosylated proteins, but developing and manufacturing such compounds comes with high expenses and risk of failure. This new consortium will combine GlycoSeLect’s glycosylation recognition technology with ForteBio’s biosensor-based analytical platform technology to develop a new glycosylation platform that will enable better characterization and monitoring of biotherapeutics products.
 
“Developing a simple, rapid and high-throughput glycoanalytical method moves us further along the path to streamline development and manufacture of biotherapeutic proteins, contributing to lower costs and faster development,” said Dr. John Liddell, CPI’s senior scientific advisor.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.